48 results about "Regulatory Pathway" patented technology

This invention describes computer based systems and methods for modeling and simulation of biochemical networks of pathways, including metabolic, signal transduction and regulatory pathways within a cell or across cells. The invention comprises systems and methods for building the models and for using the models for analysis and information retrieval, for determining the effect that modulating one or more reactions in a biochemical pathway has on an operation of the biochemical pathway, and for simulating or predicting an altered physiological state of cells.

A Candida albicans bloodstream infections cause significant morbidity and mortality in hospitalized patients. Filament formation and adherence to host cells are critical virulence factors of C. albicans. Multiple filamentation regulatory pathways have been discovered, however the downstream effectors of these regulatory pathways remain unknown. The cell surface proteins in the ALS group are downstream effectors of the filamentation regulatory pathway. Particularly, Als1p mediates adherence to endothelial cells in vitro and is required for virulence. The blocking of adherence by the organism is described resulting from the use of a composition and method disclosed herein. Specifically, a pharmaceutical composition comprised of a gene, gene product, or specific antibody to the ALS gene family is administered as a vaccine to generate an immune response capable of blocking adherence of the organism.

A method for treating or preventing cardiac hypertrophy in a mammal, comprising manipulating levels of RBP, retinoids, or an affiliated signaling and regulatory pathway in the mammal. Preferably, the method comprises reducing or inhibiting the level of RBP or retinoids or their signaling pathway, or an affiliated signaling pathway, via a dietary, genetic, protein-based, or pharmacologic approach, or a combination thereof. Also disclosed are pharmaceutical composition suitable for the method.

The invention relates generally to the use of pharmaceutical compositions to increase milk production alone or in combination with certain biological active ingredients. Specifically, the method relates to the use of pharmaceutical compositions that will act on the feedback of the intrinsic regulatory pathway in the mammalian mammary gland. The present invention provides for as a method of increasing bovine milk production as well as a method of correcting certain human lactation abnormalities. Preferably, the compounds used in the methods of the present invention are one or more active agents capable of inhibiting peripheral aromatic amino acid decarboxylase (AADC) enzymes, peripheral tryptophan hydroxylase (TPH) enzymes, peripheral serotonin (5-HT) enzymes, or a combination of enzymes thereof.

The present invention relates, e.g., to a method for generating and analyzing multi-factorial biological response profiles, comprising (a) exposing each member of a plurality of expression control sequences, each of which is operatively linked to a heterologous reporter sequence, independently, to at least about three stimuli from a first set of stimuli, wherein at least about two of the stimuli in said first set of stimuli are, optionally, combined in an intra-set combinatorial fashion; (b) detecting a first category of responses of said expression control sequences to said stimuli; and (c) generating a response profile for each of said expression control sequences. The method may further comprise (d) exposing each of said members of the plurality of expression control sequences, independently, to one or more additional sets of stimuli, optionally wherein at least about two of the stimuli in each of said additional sets of stimuli are combined in an intra-set combinatorial fashion, in an inter-set combinatorial fashion with set first set of stimuli; (e) detecting the first category of responses of said expression control sequences to the stimuli in d); and (f) generating a response profile for each of said expression control sequences, which includes the responses detected in b) and in e). Raw response profiles are preferably analyzed by multivariate statistical methods, using a computer.

A Candida albicans bloodstream infections cause significant morbidity and mortality in hospitalized patients. Filament formation and adherence to host cells are critical virulence factors of C. albicans. Multiple filamentation regulatory pathways have been discovered, however the downstream effectors of these regulatory pathways remain unknown. The cell surface proteins in the ALS group are downstream effectors of the filamentation regulatory pathway. Particularly, Als1p mediates adherence to endothelial cells in vitro and is required for virulence. The blocking of adherence by the organism is described resulting from the use of a composition and method disclosed herein. Specifically, a pharmaceutical composition comprised of a gene, gene product, or specific antibody to the ALS gene family is administered as a vaccine to generate an immune response capable of blocking adherence of the organism.

The invention provides methods and compositions for modulating the Wnt signaling pathway, in particular by interfering with binding of Dkk1 or SOST with LRP5 and / or LRP6.

A Candida albicans bloodstream infections cause significant morbidity and mortality in hospitalized patients. Filament formation and adherence to host cells are critical virulence factors of C. albicans. Multiple filamentation regulatory pathways have been discovered, however the downstream effectors of these regulatory pathways remain unknown. The cell surface protein, Als1p, is a downstream effector of the filamentation regulatory pathway and is regulated by Efg1p. Als1p mediates adherence to endothelial cells in vitro and is required for virulence. The blocking of adherence by the organism is described resulting from the use of a composition and method disclosed herein. Specifically, a pharmaceutical composition comprised of a gene product from the ALS1 gene family is administered as a vaccine to generate an immune response capable of blocking adherence of the organism.

Provided herein are methods for the diagnosis of resistance to chemotherapeutic agents by assessing the regulatory pathways of PGC1α. Methods for treating drug-resistant melanoma are also provided.

The present disclosure relates to methods for treating diseases or conditions with pulsed electromagnetic field therapy, where the disease or condition treated is one susceptible to modulation of gene expression by pulsed electromagnetic field therapy. The present disclosure generally relates to methods of modulating gene expression and biological regulatory pathways with pulsed electromagnetic field therapy for treating diseases or conditions associated with such gene expression or regulatory pathways that are susceptible to modulation by pulsed electromagnetic therapy, including diseases or conditions associated with inflammation, nerve pain and wound repair.

The present invention designs a method for studying the interaction between microRNA and protein, extracts the concept of an "indirect" target gene model, and conducts interaction research based on existing literature reports. The basic process is: Step 1, select microRNA For highly expressed cells, screen for differential proteins; step 2, prediction of microRNA target genes; step 3, introduce literature mining technology for differential protein and microRNA target genes, and build interaction network; step 4, integrate analysis results, and establish microRNA Regulatory pathways with proteins; step 5, introduce literature mining, search for literature reports that have been verified by experiments, and verify the above regulatory pathways.

The present disclosure relates to methods for treating diseases or conditions with pulsed electromagnetic field therapy, where the disease or condition treated is one susceptible to modulation of gene expression by pulsed electromagnetic field therapy. The present disclosure generally relates to methods of modulating gene expression and biological regulatory pathways with pulsed electromagnetic field therapy for treating diseases or conditions associated with such gene expression or regulatory pathways that are susceptible to modulation by pulsed electromagnetic therapy, including diseases or conditions associated with inflammation, nerve pain and wound repair.

The present invention relates to agents that modulate the Hippo pathway and Hippo pathway signaling, such as antibodies and soluble receptors, as well as to methods of using the agents for the treatment of diseases such as cancer.

Methods are provided for inhibiting or enhancing down-regulation of an antigen-activated HLA-E+ T cell by an HLA-E-restricted CD8+ T cell comprising contacting the HLA-E* T cell and CD8+ T cell with an agent which inhibits or enhances, respectively, binding between (i) T cell receptor (TCR) on the surface of the CD8+ T cell and (ii) a self peptide presented by HLA-E on the surface of the HLA-E+ T cell, thereby inhibiting or enhancing, respectively, down-regulation of the antigen-activated HLA-E+ T cell. Compositions comprising agents which inhibit or enhance / activate, respectively, binding between (i) T cell receptor (TCR) on the surface of a CD8+ T cell and (ii) a self peptide presented by HLA-E on the surface of a HLA-E+ T cell, and assays for identifying such agents, are provided.

Provided herein is a pathway for adipocyte energy consumption regulation involving ARID5B, genetic variant rs1421085, IRX3, and IRX5. Compositions and methods for modulating the pathway in vitro and in vivo for anti-cachectic and anti-obesity effects are provided. Methods of identifying subjects at risk of developing a disorder mediated by a dysregulation of the energy consumption pathway are also provided.

The invention discloses a differential gene analysis method based on BD single cell transcriptome and proteome sequencing data, and belongs to the technical field of transcriptome data analysis. In order to solve the problem that no complete data analysis method can combine single cell transcriptome and proteome sequencing data for analysis in the prior art, differential gene analysis of cell subset classification in transcription and protein levels is carried out through a single cell transcriptome and proteome sequencing technology, cell characteristics are represented, and a biological mechanism transcribed to a protein regulation expression process is obtained, and a more accurate and richer BD single cell transcriptome and proteome sequencing data combined analysis method is provided. According to the analysis method, deep understanding of differential expression can be obtained, key mRNA or protein regulated after transcription is excavated, some important regulatory pathways are found and verified, and the analysis method can be applied to the field of tumors.

The invention discloses function candidate gene for affecting the meat quality trait of a pig and a screening method of t function candidate gene. The function candidate geneisRXRG, GPI, CPT2 and / or GABARAPL1. The screening method comprises the following steps: (1), selecting longissimus muscles of two extreme pig breeds with large meat quality trait difference, extracting DNA, and independently creating databases; (2), performing whole genome DNA methylation sequencing on sample DNA databases by adoptingan MeDIP-Seq technology; (3), obtaining maps of whole genome DNA methylation levels of the two extreme pig breeds, and screeningdifferentialmethylationexpressed genes; (4), performing GO functional annotation and KEGG Pathway analysis on the differentialmethylationgenes, and screening out functional genes and regulatory pathways related to meat quality traits, such as fatty acid formation and decomposition; (5), performing DNA methylation and expression profileconjoint analysis through MeDIP-seq and RNA-seqtest results, and obtaining the function candidate gene of the meat quality trait of the pig. According to the method, the function candidate geneparticipatinginregulationof the meat quality trait of the pig is screened out, and a foundation is laid for the future deep research.

Inhibins and activins are protein hormones that reciprocally modulate a diversity of regulatory pathways. Competitive binding experiments revealed that betaglycan, the type III TGF-β receptor, also functions as an inhibin receptor. Betaglycan augments the binding of inhibin to the ActRII activin receptor. By augmenting inhibin binding to ActRII, betaglycan effectively sequesters ActRII away from activin and thereby reduces activin signaling. In addition, the ActRII-betaglycan complex may generate novel signals distinct from those initiated by activin signaling via ActRII and ALK4. Betaglycan is produced in discrete nuclei of the rat brain and by specific cell types within the adult rat pituitary, testis, and ovary. The presence of betaglycan within inhibin-responsive tissues and cell types, together with the ability of this protoglycan to bind inhibin and to confer inhibin sensitivity, is consistent with a role of betaglycan as an inhibin-specific receptor mediating inhibin responses within various tissues.

Methods are provided for inhibiting or enhancing down-regulation of an antigen-activated HLA-E+ T cell by an HLA-E-restricted CD8+ T cell comprising contacting the HLA-E+ T cell and CD8+ T cell with an agent which inhibits or enhances, respectively, binding between (i) T cell receptor (TCR) on the surface of the CD8+ T cell and (ii) a self peptide presented by HLA-E on the surface of the HLA-E+ T cell, thereby inhibiting or enhancing, respectively, down-regulation of the antigen-activated HLA-E+ T cell. Compositions comprising agents which inhibit or enhance / activate, respectively, binding between (i) T cell receptor (TCR) on the surface of a CD8+ T cell and (ii) a self peptide presented by HLA-E on the surface of a HLA-E+ T cell, and assays for identifying such agents, are provided.

The present invention provides a new means of restoring the immune system in aging and immunocompromised individuals using an antioxidant nutraceutical. The nutraceutical stimulates the aging immune system through the Nrf2 master gene regulatory pathway. The invention is based in part on the discovery that the Nrf2 has antioxidant and immune restorative activity. The nutraceutical improves function of both the innate and adaptive immune systems.

Methods are provided for inhibiting or enhancing down-regulation of an antigen-activated HLA-E+ T cell by an HLA-E-restricted CD8+ T cell comprising contacting the HLA-E+ T cell and CD8+ T cell with an agent which inhibits or enhances, respectively, binding between (i) T cell receptor (TCR) on the surface of the CD8+ T cell and (ii) a self peptide presented by HLA-E on the surface of the HLA-E+ T cell, thereby inhibiting or enhancing, respectively, down-regulation of the antigen-activated HLA-E+ T cell. Compositions comprising agents which inhibit or enhance / activate, respectively, binding between (i) T cell receptor (TCR) on the surface of a CD8+ T cell and (ii) a self peptide presented by HLA-E on the surface of a HLA-E+ T cell, and assays for identifying such agents, are provided.

The present invention provides a method of identifying an effective agent that alters the association of a Bit1 polypeptide with an AES polypeptide. The method is practiced by contacting a Bit1 polypeptide, or active fragment thereof, and an AES polypeptide, or active fragment thereof, with an agent under conditions that allow the Bit1 polypeptide or active fragment thereof to associate with the AES polypeptide or active fragment thereof; and detecting an altered association of the Bit1 polypeptide or active fragment thereof and the AES polypeptide or active fragment thereof, where an altered association indicates that the agent is an effective agent that alters the association of a Bit1 polypeptide with an AES polypeptide. Such an effective agent can modulate apoptosis and can be a useful therapeutic agent.

Compositions and methods for increasing plant yield, either directly or through selective inhibition of competing weeds, are disclosed herein. Particular focus is paid to cell cycle signaling permutations such as mutations in the DP-E2F-Rb cell cycle regulatory pathway, and to permutations in brassinolide pathways as transgenic or small-molecule targets for increasing plant yield.

The present invention provides a method of identifying an effective agent that alters the association of a Bit1 polypeptide with an AES polypeptide. The method is practiced by contacting a Bit1 polypeptide, or active fragment thereof, and an AES polypeptide, or active fragment thereof, with an agent under conditions that allow the Bit1 polypeptide or active fragment thereof to associate with the AES polypeptide or active fragment thereof; and detecting an altered association of the Bit1 polypeptide or active fragment thereof and the AES polypeptide or active fragment thereof, where an altered association indicates that the agent is an effective agent that alters the association of a Bit1 polypeptide with an AES polypeptide. Such an effective agent can modulate apoptosis and can be a useful therapeutic agent.

Calphostin C is used to treat subjects for cancer which is resistant to treatment by other forms of chemotherapeutic drugs, for example breast or uterine cancer, or other cancers characterized by tumor cells that have a defect in an apoptotic regulatory pathway which renders said cells resistant to at least some other forms of chemotherapeutic treatment. The other chemotherapeutic drug used with calphostin C is selected from the group comprising taxanes and anthracyclines, such as paclitaxel or doxorubicin. The use may take the form of administering calphostin C and then subjecting the patient to photodynamic therapy (PDT).

The invention relates to a method for constructing a eukaryotic expression vector capable of efficiently expressing pig CYP1A1 genes and belongs to the field of molecular biology. To clone the CYP1A1 genes in the pig cytochrome P450 family and construct the eukaryotic expression vector, a specific primer containing a specific digestion site and a protective base is designed, a specific coded sequence is obtained through PrimerSTAR high-fidelity enzyme cloning, and a CYP1A1 gene recombination plasmid is constructed, subjected to specific digestion treatment and connected with a linearized vector to obtain the eukaryotic expression vector pcDNA3.1(+) / zeo-CYP1A1 capable of efficiently expressing the pig CYP1A1 genes. The expression vector is used for cell metabolism and specific disease immunoreactions study, the CYP1A1 genes are effectively and excessively expressed under the driving of an efficient enhanser SV40 and an efficient promoter T7PCMV, downstream genes and corresponding regulatory pathways are activated, and cell physiological functions are affected.

The invention, which belongs to the field of biological medicines, particularly relates to application of an ILF3 detection reagent in preparation of a colorectal cancer diagnosis reagent and a colorectal cancer prognosis diagnosis reagent / kit. The research finds that ILF3 is overexpressed in a specimen of a primary CRC patient and is related to poor prognosis; and the gene is suggested to be possibly related to the malignant phenotype of CRC at the clinical level. With the molecular biological means, interference of ILF3 can significantly inhibit CRC proliferation, so that the ILF3 is shown to have an important function in colorectal cancer occurrence and development. In addition, the invention also discovers that the ILF3 promotes tumor growth by directly adjusting the mRNA stability ofthe SGOC gene and increasing the expression of the SGOC gene for the first time; that is, the ILF3 influences tumors by adjusting the SGOC pathway. Researches show that the SGOC inhibitor can be usedfor treating CRC patients with ILF3 overexpression and has important clinical significance.

A method for increasing the efficiency of homologous recombination-based gene editing in a plant according to an embodiment of the present invention includes optimizing temperature and photoperiod conditions during tissue culture of plant cells, expressing factors required for homology-directed DNA repair (HDR) and factors for increasing the HDR efficiency by using a multiple replicon, or regulating the HDR pathway or non-homologous end joining (NHEJ) pathway.

The invention discloses a construction method of a biosensor capable of dynamically promoting high yield of 3HP (3-hydroxypropionic acid) and aims to eliminate the contradiction that in the 3HP synthesis process, an overexpressed malonyl CoA carboxylase gene (acc) can increase the yield of 3HP but excessive synthesized malonyl CoA poisons bacteria. A transcription factor FapR is sensitive to malonyl CoA, a negative feedback regulatory pathway is designed by use of the FapR and a promoter sequence to regulate transcription according to the concentration of malonyl CoA, the synthesis and transformation rate of malonyl CoA is controlled, and the yield of 3HP is increased while poisoning to bacterium cells is avoided. Experiments at the early stage discover that the malonyl CoA sensing controller can dynamically regulate the pathway and increase the yield of 3HP.